Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models. Issue 9 (1st July 2015)

• Record Type: Journal Article
• Authors: Arntz, Onno J.; Pieters, Bartijn C.H.; Oliveira, Marina C.; Broeren, Mathijs G.A.; Bennink, Miranda B.; de Vries, Marieke; van Lent, Peter L.E.M.; Koenders, Marije I.; van den Berg, Wim B.; van der Kraan, Peter M.; van de Loo, Fons A.J.
• Is Part Of: Molecular nutrition & food research. Volume 59:Issue 9(2015:Sep.)
• Page Start: 1701
• Page End: 1712
• Publication Date: 2015-07-01
• Subjects: Food -- Biotechnology -- Periodicals; Food -- Microbiology -- Periodicals; Nutrition -- Periodicals; Food -- Toxicology -- Periodicals; Nutrition -- Periodicals; Food Microbiology -- Periodicals; Food Technology -- Periodicals; Molecular Biology -- Periodicals; 664.0705
• DOI: 10.1002/mnfr.201500222
• Languages: English
• ISSNs: 1613-4125

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="mnfr2424-sec-0010" sec-type="section"> <title>Scope</title> <p>This study shows the effect of bovine milk derived extracellular vesicles (BMEVs) on spontaneous polyarthritis in IL‐1Ra‐deficient mice and collagen‐induced arthritis.</p> </sec> <sec id="mnfr2424-sec-0020" sec-type="section"> <title>Methods and results</title> <p>BMEVs were isolated from semi‐skimmed milk by ultracentrifugation and the particle size was around 100 nm by dynamic light scattering and electron microscopy. BMEVs expressed exosome marker CD63, immunoregulatory microRNA's (miR‐30a, ‐223, ‐92a), and milk‐specific beta‐casein and beta‐lactoglobulin mRNA. In vitro, PKH‐67‐labeled BMEVs were taken up by RAW264.7, splenocytes, and intestinal cells as determined by flow cytometry and confocal microscopy. IL‐1Ra<sup>−/−</sup> mice received BMEVs by daily oral gavage starting at wk 5 till 15 after birth and collagen‐induced arthritis mice via their drinking water starting 1 wk before immunization till day 40. Macroscopically, BMEV treatment delayed the onset of arthritis and histology showed diminished cartilage pathology and bone marrow inflammation in both models. BMEV treatment also reduced the serum levels of MCP‐1 and IL‐6 and their production by splenic cells. BMEV treatment diminished the anticollagen IgG2a levels, which was accompanied by reduced splenic Th1 (Tbet) and Th17 (RORγT) mRNA.</p> </sec> <sec id="mnfr2424-sec-0030" sec-type="section"> <title>Conclusion</title> <p>This is the first report that oral delivery of BMEVs ameliorates experimental arthritis and this warrants further research to determine whether this beneficial effect can be seen in rheumatoid arthritis patients.</p> </sec> </abstract>